Aldose reductase inhibitors

W. R. Kirchain, M. S. Rendell

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The present management of diabetes consists of attempting to control blood sugar tightly in the normal range and to treat individual complications such as neuropathy and retinopathy as they appear. Whereas these measures are perhaps effective in slowing the progress of diabetic complications, they do not cure the underlying process. The aldose reductase inhibitors have been investigated as possible remedies for various diabetic complications. Aldose reductase is an enzyme present in several human tissues that reduces glucose to sorbitol. In animal models there is evidence that the production of sorbitol is associated with the development of diabetic complications. Animal and human studies have tested the ability of aldose reductase inhibitors to halt or reverse diabetic complications. The weight of evidence leads to two conclusions: first, that aldose reductase inhibitors may bring significant relief to patients with certain diabetic complications; and second, that the current approach to proving clinical efficacy may not be adequate for these drugs.

Original languageEnglish
Pages (from-to)326-336
Number of pages11
JournalPharmacotherapy
Volume10
Issue number5
StatePublished - 1990

Fingerprint

Aldehyde Reductase
Diabetes Complications
Sorbitol
Blood Glucose
Reference Values
Animal Models
Weights and Measures
Glucose
Enzymes
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kirchain, W. R., & Rendell, M. S. (1990). Aldose reductase inhibitors. Pharmacotherapy, 10(5), 326-336.

Aldose reductase inhibitors. / Kirchain, W. R.; Rendell, M. S.

In: Pharmacotherapy, Vol. 10, No. 5, 1990, p. 326-336.

Research output: Contribution to journalArticle

Kirchain, WR & Rendell, MS 1990, 'Aldose reductase inhibitors', Pharmacotherapy, vol. 10, no. 5, pp. 326-336.
Kirchain WR, Rendell MS. Aldose reductase inhibitors. Pharmacotherapy. 1990;10(5):326-336.
Kirchain, W. R. ; Rendell, M. S. / Aldose reductase inhibitors. In: Pharmacotherapy. 1990 ; Vol. 10, No. 5. pp. 326-336.
@article{b55a21032e96433daec63a7105003447,
title = "Aldose reductase inhibitors",
abstract = "The present management of diabetes consists of attempting to control blood sugar tightly in the normal range and to treat individual complications such as neuropathy and retinopathy as they appear. Whereas these measures are perhaps effective in slowing the progress of diabetic complications, they do not cure the underlying process. The aldose reductase inhibitors have been investigated as possible remedies for various diabetic complications. Aldose reductase is an enzyme present in several human tissues that reduces glucose to sorbitol. In animal models there is evidence that the production of sorbitol is associated with the development of diabetic complications. Animal and human studies have tested the ability of aldose reductase inhibitors to halt or reverse diabetic complications. The weight of evidence leads to two conclusions: first, that aldose reductase inhibitors may bring significant relief to patients with certain diabetic complications; and second, that the current approach to proving clinical efficacy may not be adequate for these drugs.",
author = "Kirchain, {W. R.} and Rendell, {M. S.}",
year = "1990",
language = "English",
volume = "10",
pages = "326--336",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Aldose reductase inhibitors

AU - Kirchain, W. R.

AU - Rendell, M. S.

PY - 1990

Y1 - 1990

N2 - The present management of diabetes consists of attempting to control blood sugar tightly in the normal range and to treat individual complications such as neuropathy and retinopathy as they appear. Whereas these measures are perhaps effective in slowing the progress of diabetic complications, they do not cure the underlying process. The aldose reductase inhibitors have been investigated as possible remedies for various diabetic complications. Aldose reductase is an enzyme present in several human tissues that reduces glucose to sorbitol. In animal models there is evidence that the production of sorbitol is associated with the development of diabetic complications. Animal and human studies have tested the ability of aldose reductase inhibitors to halt or reverse diabetic complications. The weight of evidence leads to two conclusions: first, that aldose reductase inhibitors may bring significant relief to patients with certain diabetic complications; and second, that the current approach to proving clinical efficacy may not be adequate for these drugs.

AB - The present management of diabetes consists of attempting to control blood sugar tightly in the normal range and to treat individual complications such as neuropathy and retinopathy as they appear. Whereas these measures are perhaps effective in slowing the progress of diabetic complications, they do not cure the underlying process. The aldose reductase inhibitors have been investigated as possible remedies for various diabetic complications. Aldose reductase is an enzyme present in several human tissues that reduces glucose to sorbitol. In animal models there is evidence that the production of sorbitol is associated with the development of diabetic complications. Animal and human studies have tested the ability of aldose reductase inhibitors to halt or reverse diabetic complications. The weight of evidence leads to two conclusions: first, that aldose reductase inhibitors may bring significant relief to patients with certain diabetic complications; and second, that the current approach to proving clinical efficacy may not be adequate for these drugs.

UR - http://www.scopus.com/inward/record.url?scp=0025145117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025145117&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 326

EP - 336

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -